S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

BioXcel Therapeutics Stock Price, Forecast & Analysis (NASDAQ:BTAI)

$5.86
+0.71 (+13.79 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$5.24
Now: $5.86
$6.17
50-Day Range
$4.00
MA: $5.44
$7.74
52-Week Range
$2.41
Now: $5.86
$12.00
Volume417,900 shs
Average Volume70,283 shs
Market Capitalization$92.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.8
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTAI
CUSIPN/A
Phone203-643-8060

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.49 per share

Profitability

Net Income$-19,270,000.00

Miscellaneous

Employees18
Market Cap$92.19 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.


BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced its earnings results on Thursday, November, 14th. The company reported ($0.57) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.02. View BioXcel Therapeutics' Earnings History.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for BioXcel Therapeutics.

What price target have analysts set for BTAI?

4 brokers have issued 12-month price objectives for BioXcel Therapeutics' stock. Their forecasts range from $21.00 to $25.00. On average, they anticipate BioXcel Therapeutics' share price to reach $22.75 in the next twelve months. This suggests a possible upside of 288.2% from the stock's current price. View Analyst Price Targets for BioXcel Therapeutics.

What is the consensus analysts' recommendation for BioXcel Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.

What are Wall Street analysts saying about BioXcel Therapeutics stock?

Here are some recent quotes from research analysts about BioXcel Therapeutics stock:
  • 1. According to Zacks Investment Research, "BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. " (9/11/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We utilize a discounted cash flow (DCF)-based assessment, which yields a total rNPV of $335M for for BXCL701. We thus derive a total enterprise value of $455M, which translates into a price objective of $25.00 based on 18M fully-diluted shares outstanding as of end-3Q19." (1/4/2019)

Has BioXcel Therapeutics been receiving favorable news coverage?

Media stories about BTAI stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioXcel Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for BioXcel Therapeutics.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totalling 491,400 shares, an increase of 19.6% from the September 30th total of 410,800 shares. Based on an average daily volume of 71,900 shares, the days-to-cover ratio is presently 6.8 days. Currently, 7.3% of the shares of the stock are short sold. View BioXcel Therapeutics' Current Options Chain.

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the folowing people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
  • Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (7.57%), California Public Employees Retirement System (2.01%), Strs Ohio (0.05%) and Rational Advisors LLC (0.04%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Institutional Ownership Trends for BioXcel Therapeutics.

Which institutional investors are buying BioXcel Therapeutics stock?

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, California Public Employees Retirement System, Strs Ohio and Rational Advisors LLC. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Insider Buying and Selling for BioXcel Therapeutics.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $5.86.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $92.19 million. The company earns $-19,270,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.View Additional Information About BioXcel Therapeutics.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is http://www.bioxceltherapeutics.com/.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-643-8060 or via email at [email protected]roup.com.


MarketBeat Community Rating for BioXcel Therapeutics (NASDAQ BTAI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote "Outperform" if you believe BTAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Convertible Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel